 |
17 Diseases |  |
8 Trials |
|
8 Trials |  |
676 News |  |
| «12345678910» |
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Selexipag for the Treatment of Schistosomiasis-associated Pulmonary Arterial Hypertension - The SELSCH Study (San Diego Convention Center, Room 25A-C (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_8124;
It was well tolerated, despite the incidence of side effects during the titration phase. The SELSCH study is the first one to demonstrate the prospective efficacy of a specific PAH therapy in the schistosomiasis population.
- Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, Uptravi (selexipag) / J&J, Nippon Shinyaku
Pharmaceutical Industry Payments to Physicians and Prescriptions of Oral Pulmonary Arterial Hypertension Medications (San Diego Convention Center, Room 11A-B (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_8043;
Physicians receiving non-research payments from industry related to oral treprostinil and oral selexipag were more likely to prescribe these costly medications associated with high Medicare expenditures, despite payments being overall low value. Investigation is needed to understand the role of industry in shaping physician behavior and practice related to treating PAH.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Selexipag in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (PAH-CTD): Real-world Evidence From EXPOSURE (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6476;
Conclusions In this contemporary real-world analysis, PAH-CTD patients most commonly initiated selexipag as part of a triple combination therapy. Length of time from diagnosis and extent of disease severity at selexipag initiation suggest an opportunity for earlier treatment escalation.
- methamphetamine / Generic mfg.
Case Series: Marked Attenuation of Methamphetamine-associated Pulmonary Arterial Hypertension With Methamphetamine Cessation and Pharmacologic Therapy (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6468;
Disease progression led to the addition of tadalafil and macitentan...She was initiated on ambrisentan, but intolerant of selexipag and PDE5i...Sildenafil and ambrisentan were initiated, with simultaneous methamphetamine cessation...He was initiated on subcutaneous Treprostinil infusion and PDE5i, with total methamphetamine cessation...Methamphetamine cessation combined with pulmonary vasodilator therapies appear to unmask a possible endotype within meth-APAH that demonstrate capability for greatly ameliorated disease. Further studies to better phenotype meth-APAH and investigate the role of methamphetamine cessation combined with PAH pharmacotherapy in altering disease course are warranted.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Expert Consensus on Best Practices for Oral Selexipag Titration and Management of Expected Side Effects in the Treatment of Pulmonary Arterial Hypertension (PAH) (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5771;
This Delphi Panel of experienced PAH clinicians found consensus on proactive communication, management of expected SE, and flexibility with timing of dose increases when treating PAH patients with oral selexipag. This work is ongoing and promises to support standardized approaches to selexipag use that may improve patient adherence to treatment and clinical outcomes.
- Uptravi Injection (selexipag IV) / J&J, Nippon Shinyaku, Uptravi (selexipag) / J&J, Nippon Shinyaku
Intravenous Selexipag Uptitration for Decompensated Right Ventricular Failure in Pulmonary Arterial Hypertension: A Novel Approach (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3891;
Transitioning to the oral formulation improved convenience and facilitated continued therapy post-discharge. Further study is warranted to evaluate the efficacy, safety, and long-term outcomes of this approach.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Pulmonary Hypertension Due to Unilateral Absence of Pulmonary Artery: A Series of 2 Cases (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3875;
She refused parenteral therapy for PAH and was started on oral therapy with tadalafil 40 mg daily, ambrisentan 10 mg daily and Selexipag...She was started on inhaled nitric oxide transitioned to IV Treprostinil and sildenafil 40 mg TID...Therefore, pharmacotherapy with vasodilators is largely pursued. These cases highlight the need for awareness of this condition as treatment varies based on the age of diagnosis.
- Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Nippon Shinyaku
"Pop n' Drop": Two Cases of Recreational Amyl Nitrite Use Among Patients With Pulmonary Arterial Hypertension on Phosphodiesterase-5 Inhibitors Leading to Syncope (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3872;
There are major drug interactions when amyl nitrites are taken with phosphodiesterase-5 inhibitors (PDE5i) such as sildenafil or tadalafil, resulting in profound hypotension and resultant loss of consciousness...Case Presentations: Case 1: 49-year-old male with history of WHO group I PAH secondary to HIV and methamphetamine use, on tadalafil, ambrisentan and selexipag, notes ongoing light-headedness and pre-syncope during sexual intercourse but not during other vigorous activities...Although the drug interaction between nitrates and PDE5i and riociguat is well-established, it is not commonplace to discuss the avoidance of poppers in patients with PAH. MSM on PD5i or riociguat for PAH should be screened for amyl nitrite exposure and informed of potential adverse drug interactions to prevent syncope.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Improvement in PAH After Semaglutide-induced Weight Loss (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3871;
She was initiated on intravenous Epoprostenol and had improvement in symptoms to WHO FC II...She was transitioned to oral therapy with selexipag and ambrisentan...Table 1. Clinical and echocardiogram-derived markers of pulmonary hypertension severity by date.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Unique Presentation of Pulmonary Veno-occlusive Disease in Patient Whose Mother Had Familial Pulmonary Arterial Hypertension (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3870;
At age 29 he was receiving tadalafil, ambrisentan, and selexipag...Selexipag was discontinued and IV treprostinil was initiated...The pathology in the patient's mother was consistent with PAH while his pathology revealed PVOD. This case raises the question of a "crossover" genetic variant within pulmonary vascular disease with a PAH phenotype in the proband and a PVOD phenotype in the subsequent generation vs. a novel spectrum of disease evolution.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Rapid Inpatient Parenteral to Oral Prostacyclin Transition Therapy in High Risk PAH Patients With Relative Contraindications to Outpatient Intravenous Therapy: A Retrospective Case Series (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1720;
Although some high-risk PAH patients have contraindications to outpatient parenteral therapy, they may benefit from a short, rapid, inpatient parenteral titration treatment to assist in RV recovery with transition to an oral prostacyclin prior to discharge. Patients can experience improvement in functional class prior to discharge, with stable symptoms on triple oral therapy at long-term follow-up.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
SELEXIPAG FOR THE TREATMENT OF SEVERE DIGITAL VASCULOPATHY IN SYSTEMIC SCLEROSIS: LONG-TERM CLINICAL AND PERFUSION RESULTS (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_339;
Selexipag showed a good safety profile and a significant improvement in clinical manifestations and digital perfusion without the influence of seasonal variability. These encouraging results have to be confirmed by new trials designed for the evaluation of selexipag efficacy in SSc digital vasculopathy.
- TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_225;
This is the first meta-analysis on CTD-PAH that reported the pooled analysis of change in functional class, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have important prognostic value for PAH. Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH).
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs. (Pubmed Central) - Feb 9, 2024
Here we report cryo-electron microscopy (cryo-EM) structures of the human IP-Gs complex bound with two anti-PAH drugs, treprostinil and MRE-269 (active form of selexipag), at global resolutions of 2.56 and 2.41 angstrom, respectively...Combined with molecular docking and functional studies, our structures provide insight into agonist selectivity, ligand recognition, receptor activation, and G protein coupling. Our results provide a structural template for further improving IP-targeting drugs to reduce off-target activation of prostanoid receptors and adverse effects.
- || Review, Journal: Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. (Pubmed Central) - Jan 26, 2024
However, the long-term effects of these medications on PAH-CHD patients remain somewhat uncertain, necessitating treatment plans largely founded on the clinical experience of the healthcare providers. The aim of this review is to summarize the current evidence and future perspectives regarding treatment strategies for PAH-CHD to help better guide management of this complex disease.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
METASTATIC MULLERIAN CANCER MASQUERADING AS PRIMARY PULMONARY ARTERIAL HYPERTENSION (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4118;
Unexplained new PH should prompt consideration for new malignancy if other work-up (connective tissue disease is unremarkable. Although not done here, wedge aspiration cytology could also be helpful to differentiate tumoral PH.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
SARCOIDOSIS ASSOCIATED PULMONARY HYPERTENSION PRESENTING AS CARDIOGENIC SHOCK (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3701;
She also initiated selexipag with outpatient uptitration... PH is a serious manifestation of sarcoidosis that can present as RV cardiogenic shock requiring prompt evaluation and treatment.
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal, Real-world evidence, Real-world: Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). (Pubmed Central) - Jan 15, 2024
P=N/A
In this real-world analysis of patients initiating selexipag, most patients had stable or improved FC and REVEAL 2.0 risk category. Similar to the GRIPHON trial, outcomes with selexipag in this real-world study were comparable across maintenance dose strata, with no new safety signals.
- | Uptravi Injection (selexipag IV) / J&J, Nippon Shinyaku, Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: PULMOEAST: A Comprehensive Analysis of Pulmonary Hypertension in Eastern India. (Pubmed Central) - Jan 11, 2024
However, the diverse etiologies, limited access to PH-specific resources, and lack of widespread awareness within the region continue to pose substantial challenges for patients. The study underscores the need for refined diagnostic approaches, cost-effective management strategies, collaborative care initiatives, and enhanced patient education to optimize PH care and improve outcomes in eastern India.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil (Board #137; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1719;
Notably, both these transitions occurred without invasive hemodynamic monitoring and were well tolerated with no hemodynamic compromise and only mild joint pain. Upon discharge, treprostinil was transitioned to subcutaneous administration per patient preference, with planned outpatient uptitration to goal dose based on hemodynamics and side effect profiles.Summary This approach outlines a safe 4-day transition from selexipag to IV treprostinil and challenges the need for concurrent invasive hemodynamic monitoring.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Uptravi (selexipag) / J&J, Nippon Shinyaku
Pulmonary Arterial Hypertension Associated to Tyrosine Kinase Inhibitor - A Case Report (Board #136; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1718;
A new TKI-therapy was started (ponatinib)...Follow-up RHC verified the improvement, with PAPm 25mmHg and PVR 2,3 WU.Summary We present a case of imatinib-induced PAH with typical clinical characteristics. Further research is necessary to address the role of TKI in PAH, identifying predisposing factors, tolerability and the duration of treatment.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Treatment Patterns for Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 - A Descriptive Real-World Cohort Study (FINPAH) (Board #122; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1349;
During one year, risk category improved for 38%, 58% and 17% after PEA, BPA and initiation of drug therapy, respectively.Conclusion Many patients were on monotherapy one year after diagnosis, and few used combination treatment with selexipag or PCA in opposite of the guidelines. With treatment initiation, a majority of the patients improved risk category and 34 % achieved low risk.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Survival in Pulmonary Arterial Hypertension (PAH) for 669 Patients Treated with Selexipag in Clinical Practice: Insights from EXPOSURE (South Hall 1) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_588;
Applying propensity score weighting provided treatment groups that mimic randomization, including similar treatment exposure. Weighted proportion of deaths was lower in the selexipag vs other PAH therapy cohort and MRR showed, a statistically significant, better survival for patients treated with selexipag (MRR=0.55).Conclusion When baseline patient characteristics are accounted for, survival analyses in EXPOSURE demonstrated a 45% reduction in mortality among patients treated with selexipag vs other PAH therapies.
- || Uptravi (selexipag) / J&J, Nippon Shinyaku
Retrospective data, Review, Journal, HEOR: Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis. (Pubmed Central) - Jan 2, 2024
Weighted proportion of deaths was lower in the selexipag vs other PAH therapy cohort and MRR showed, a statistically significant, better survival for patients treated with selexipag (MRR=0.55).Conclusion When baseline patient characteristics are accounted for, survival analyses in EXPOSURE demonstrated a 45% reduction in mortality among patients treated with selexipag vs other PAH therapies. No differences in 6MWD change, clinical worsening reduction and adverse events rates were found among oral treprostinil and selexipag, resulting in similar efficacy and safety profile.
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal, Adverse events, Patient reported outcomes: Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag. (Pubmed Central) - Dec 18, 2023
No differences in 6MWD change, clinical worsening reduction and adverse events rates were found among oral treprostinil and selexipag, resulting in similar efficacy and safety profile. The PRO-CTCAE items selected in this study and the additional symptomatic AEs identified as patient-relevant have the potential to be included in assessments capturing the patient perspective on tolerability in future studies of selexipag and possibly other PAH therapies.
- Uptravi (selexipag) / J&J
Trial termination, MRI: RESTORE: A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (clinicaltrials.gov) - Dec 15, 2023
P4, N=9, Terminated, Sponsor: Actelion
The PRO-CTCAE items selected in this study and the additional symptomatic AEs identified as patient-relevant have the potential to be included in assessments capturing the patient perspective on tolerability in future studies of selexipag and possibly other PAH therapies. Completed --> Terminated; The Sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate.
- | vilanterol (GW642444H) / GSK, Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: In silico drug screen reveals potential competitive MTHFR inhibitors for clinical repurposing. (Pubmed Central) - Dec 5, 2023
Our results could guide the development of novel MTHFR inhibitor compounds, which could be inspired by the drugs brought into the spotlight here. More importantly, these potential candidates could be quhickly tested as a repurposing strategy in pre-clinical and clinical studies of the cancers mentioned above.Communicated by Ramaswamy H. Sarma.
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal, Adverse events, Real-world evidence, Real-world: A real-world analysis of safety profile of selexipag by using FDA adverse event Reporting System (FAERS). (Pubmed Central) - Nov 30, 2023
Within the pediatric population, unexpected signals such as pyrexia, pneumonia, and intussusception necessitate special precautionary measures. The findings contribute valuable insights to clinical practice, reinforcing the importance of vigilant monitoring, and can be instrumental in guiding both therapeutic applications and safety assessments of this particular medication.
- || Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion date, Trial primary completion date: INSPECTIO: A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (clinicaltrials.gov) - Nov 8, 2023
P=N/A, N=186, Active, not recruiting, Sponsor: Janssen-Cilag S.p.A.
The findings contribute valuable insights to clinical practice, reinforcing the importance of vigilant monitoring, and can be instrumental in guiding both therapeutic applications and safety assessments of this particular medication. Trial completion date: Dec 2024 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
- Uptravi (selexipag) / J&J
Trial completion, MRI: RESTORE: A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (clinicaltrials.gov) - Nov 8, 2023
P4, N=9, Completed, Sponsor: Actelion
Trial completion date: Dec 2024 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024 Active, not recruiting --> Completed
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension. (Pubmed Central) - Nov 3, 2023
Currently, only oral selexipag (OS) and oral treprostinil (OT) have this mechanism of action and are available in the United States (US)...Using OS was associated with 22.3% cost reduction and 39.1% hospitalizations averted; the number of patients needed treated with selexipag to avoid one hospital admission was 1.23. OWSA indicated medication cost was the most sensitive parameter, followed by population parameters.Limitations and OS use over two years would result in lower total, drug, and hospitalization-related costs compared with OT, thus providing financial savings for payers.
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J, Nippon Shinyaku
CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_1582;
Importantly, CS585 does not affect coagulation parameters and previous studies demonstrated no potential for increased bleeding in mouse models. Overall, CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP receptor on platelets for primary inhibition of thrombosis with a reduced risk of bleeding.
- |||| Uptravi (selexipag) / J&J
Enrollment closed: SALTO: A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 11, 2023
P3, N=138, Active, not recruiting, Sponsor: Actelion
Overall, CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP receptor on platelets for primary inhibition of thrombosis with a reduced risk of bleeding. Recruiting --> Active, not recruiting
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Retrospective data, Journal, HEOR: Impact of selexipag use within 12?months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study. (Pubmed Central) - Oct 7, 2023
Recruiting --> Active, not recruiting Selexipag initiation within 12?months of PAH diagnosis demonstrated reductions in all-cause hospitalization rate and medical costs.
- | Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
Journal: Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in bmpr2-silenced human lung microvascular endothelial cells. (Pubmed Central) - Oct 4, 2023
Our findings highlight the potential role of BMPRII signaling pathway in driving pulmonary endothelial cell angiogenesis. In addition, PAH drugs display limited effects on endothelial function when BMPRII is impaired, suggesting that innovative therapeutic strategies targeting BMPRII signaling are needed to better rescue endothelial dysfunction in PAH.
- || Review, Journal: Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases. (Pubmed Central) - Sep 28, 2023
We aim to review the literature on recent advances in the treatment strategy and prognosis of patients with PAH-CTD. In this manuscript, we discuss the mechanism of action of PAH-specific drugs and new agents and the latest research conducted on PAH-CTD patients.
- Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3585;
This is the first meta-analysis on CTD-PAH that reported the pooled analysis of change in functional class, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have important prognostic value for PAH. Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH).
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J, Nippon Shinyaku
Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3581;
PGs can be beneficial in the short term to reduce the severity of SSc-associated RP. Therefore, PG may be considered a therapeutic option in people with SSc-associated RP.
- || Uptravi (selexipag) / J&J, Nippon Shinyaku
Retrospective data, Review, Journal: Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis. (Pubmed Central) - Sep 23, 2023
When treatment lasted for more than 6?months, selexipag exerted obvious effects, even in the low-dosage group. This finding is important for guiding individualized treatments.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING SELEXIPAG IN THE SPHERE REGISTRY BY RACE AND ETHNICITY (Convention Center Exhibit Hall) - Sep 15, 2023 - Abstract #CHEST2023CHEST_6304;
- | Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: PHoenix: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (clinicaltrials.gov) - Aug 22, 2023
P4, N=40, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
This finding is important for guiding individualized treatments. Not yet recruiting --> Recruiting
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension. (Pubmed Central) - Aug 14, 2023
Like treprostinil, MRE-269, an IP receptor agonist, and butaprost, an EP receptor agonist, attenuated DRP1-mediated mitochondrial fragmentation through PKA. We conclude that prostacyclin mimetics produce their anti-proliferative effects on PAH PASMCs in part by inhibiting DRP1-mediated mitochondrial fragmentation.
- GROUP 5 PULMONARY HYPERTENSION ASSOCIATED WITH T-CELL LGL LEUKEMIA: HEMODYNAMICS AND TREATMENT (Convention Center 323A) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4922;
- RIGHT BRONCHUS COMPRESSION DUE TO ENLARGED PULMONARY ARTERY SECONDARY TO IDIOPATHIC PULMONARY HYPERTENSION (Convention Center Exhibit Hall - Rapid Area 4C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4882;
- RARE CASE REPORT:YOUNG CHILD WITH VASCULOPATHY ASSOCIATED WITH STIMULATOR OF INTERFERON GENES AND SEVERE PULMONARY ARTERIAL HYPERTENSION BUT WITHOUT INTERSTITIAL LUNG DISEASE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4222;
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry. (Pubmed Central) - Jul 15, 2023
We conclude that prostacyclin mimetics produce their anti-proliferative effects on PAH PASMCs in part by inhibiting DRP1-mediated mitochondrial fragmentation. Transition from selexipag to oral treprostinil was safe, performed without parenteral prostacyclin bridging, and resulted in clinical and categorical risk improvements in some patients.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial completion, Trial completion date: SPHINX: A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (clinicaltrials.gov) - Jul 3, 2023
P2, N=10, Completed, Sponsor: Actelion
Transition from selexipag to oral treprostinil was safe, performed without parenteral prostacyclin bridging, and resulted in clinical and categorical risk improvements in some patients. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Four-strata risk assessment in pulmonary arterial hypertension (PAH) patients treated with selexipag in real-world settings: Insights from EXPOSURE (PS-19 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_3993;
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023 Cell and molecular biology; Pulmonary function testing; General respiratory patient care; Epidemiology; Respiratory intensive care; Public health; Physiology
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report. (Pubmed Central) - May 25, 2023
Cell and molecular biology; Pulmonary function testing; General respiratory patient care; Epidemiology; Respiratory intensive care; Public health; Physiology No abstract available
- | Uptravi (selexipag) / J&J, Nippon Shinyaku
Journal: Antiproliferative effect of selexipag active metabolite MRE-269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension. (Pubmed Central) - May 14, 2023
This is the first study to demonstrate the pharmacological effects on PASMCs from CTEPH patients of a drug approved for the treatment of CTEPH. Both the vasodilatory and the antiproliferative effect of MRE-269 may contribute to the efficacy of selexipag in CTEPH.